论文部分内容阅读
作者报道了10例恶性胶质瘤原发进展性或复发性病例接受T细胞免疫疗法的经验。并对其治疗方法进行了具体的描述及临床意义评估。 临床资料:全部病例均为病理诊断的Ⅲ～Ⅳ级恶性星型细胞瘤,最初确诊后均进行过放疗,4例曾行化疗。免疫治疗前,8例证实为肿瘤复发,2例原发性多形性胶质母细胞瘤(GBM)放疗后有明显肿瘤残余或复发的影像学表现。接受T细胞免疫疗法前4周未行化疗、放疗及其他免疫疗法。从手术中获取肿瘤标本至接受治疗的时间多为10～14周。
The authors reported 10 cases of primary malignant gliomas or recurrent progressive cases of T cell immunotherapy experience. And the treatment of its specific description and clinical evaluation. Clinical data: All cases were pathologically diagnosed grade Ⅲ ~ Ⅳ malignant astrocytoma, were initially diagnosed with radiotherapy, 4 patients had chemotherapy. Before immunotherapy, 8 cases were confirmed as tumor recurrence, and 2 cases showed significant tumor residual or recurrence after radiotherapy of primary glioblastoma multiforme (GBM). 4 weeks before receiving T cell immunotherapy, chemotherapy, radiotherapy and other immunotherapy. Tumor samples from surgery to receive treatment for the most time is 10 to 14 weeks.